Analysis of renal impairment in MM-003: a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure. The phase III trial MM-003 compared pomalidomide + low-dose dexamethasone with high-dose dexamethasone. This subanalysis grouped...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 14, 2016
|
| In: |
Haematologica
Year: 2016, Jahrgang: 101, Heft: 7, Pages: 872-878 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2015.137083 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2015.137083 Verlag, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004467/ 
|
| Verfasserangaben: | Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, Martha Q. Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Stefan Knop, Xin Yu, Kevin Hong, Lars Sternas, Christian Jacques, Mohamed H. Zaki, and Jesus San Miguel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1569935882 | ||
| 003 | DE-627 | ||
| 005 | 20220814075053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180216s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2015.137083 |2 doi | |
| 035 | |a (DE-627)1569935882 | ||
| 035 | |a (DE-576)499935888 | ||
| 035 | |a (DE-599)BSZ499935888 | ||
| 035 | |a (OCoLC)1340987450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Weisel, Katja |d 1971- |e VerfasserIn |0 (DE-588)118014935 |0 (DE-627)079191975 |0 (DE-576)291668887 |4 aut | |
| 245 | 1 | 0 | |a Analysis of renal impairment in MM-003 |b a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma |c Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, Martha Q. Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Stefan Knop, Xin Yu, Kevin Hong, Lars Sternas, Christian Jacques, Mohamed H. Zaki, and Jesus San Miguel |
| 264 | 1 | |c April 14, 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.02.2108 | ||
| 520 | |a Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure. The phase III trial MM-003 compared pomalidomide + low-dose dexamethasone with high-dose dexamethasone. This subanalysis grouped patients by baseline creatinine clearance ≥ 30 − < 60 mL/min (n=93, pomalidomide + low-dose dexamethasone; n=56, high-dose dexamethasone) or ≥ 60 mL/min (n=205, pomalidomide + low-dose dexamethasone; n=93, high-dose dexamethasone). Median progression-free survival was similar for both subgroups and favored pomalidomide + low-dose dexamethasone versus high-dose dexamethasone: 4.0 versus 1.9 months in the group with baseline creatinine clearance ≥ 30 − < 60 mL/min (P<0.001) and 4.0 versus 2.0 months in the group with baseline creatinine clearance ≥ 60 mL/min (P<0.001). Median overall survival for pomalidomide + low-dose dexamethasone versus high-dose dexamethasone was 10.4 versus 4.9 months (P=0.030) and 15.5 versus 9.2 months (P=0.133), respectively. Improved renal function, defined as an increase in creatinine clearance from < 60 to ≥ 60 mL/min, was similar in pomalidomide + low-dose dexamethasone and high-dose dexamethasone patients (42% and 47%, respectively). Improvement in progression-free and overall survival in these patients was comparable with that in patients without renal impairment. There was no increase in discontinuations of therapy, dose modifications, and adverse events in patients with moderate renal impairment. Pomalidomide at a starting dose of 4 mg + low-dose dexamethasone is well tolerated in patients with refractory or relapsed and refractory multiple myeloma, and of comparable efficacy if moderate renal impairment is present. This trial was registered with clinicaltrials.gov identifier 01311687 and EudraCT identifier 2010-019820-30. | ||
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 101(2016), 7, Seite 872-878 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Analysis of renal impairment in MM-003 a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:101 |g year:2016 |g number:7 |g pages:872-878 |g extent:7 |a Analysis of renal impairment in MM-003 a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2015.137083 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004467/ |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180216 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1569935882 |e 2999470568 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Katja","display":"Weisel, Katja","family":"Weisel"},{"given":"Hartmut","role":"aut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Analysis of renal impairment in MM-003","subtitle":"a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma","title_sort":"Analysis of renal impairment in MM-003"}],"origin":[{"dateIssuedDisp":"April 14, 2016","dateIssuedKey":"2016"}],"note":["Gesehen am 16.02.2108"],"id":{"eki":["1569935882"],"doi":["10.3324/haematol.2015.137083"]},"recId":"1569935882","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"814204899","id":{"eki":["814204899"],"zdb":["2805244-4"],"issn":["1592-8721"]},"title":[{"subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation","title_sort":"Haematologica","title":"Haematologica"}],"pubHistory":["99.2014 -"],"note":["Gesehen am 27.05.2022"],"origin":[{"dateIssuedDisp":"2014-","dateIssuedKey":"2014","publisher":"Ferrata Storti Foundation","publisherPlace":"Pavia"}],"disp":"Analysis of renal impairment in MM-003 a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myelomaHaematologica","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"titleAlt":[{"title":"journal of the European Hematology Association"}],"part":{"volume":"101","extent":"7","text":"101(2016), 7, Seite 872-878","issue":"7","year":"2016","pages":"872-878"}}],"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, Martha Q. Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Stefan Knop, Xin Yu, Kevin Hong, Lars Sternas, Christian Jacques, Mohamed H. Zaki, and Jesus San Miguel"]}} | ||
| SRT | |a WEISELKATJANALYSISOF1420 | ||